Teva Pharmaceutical Industries (TEVA) Raises Revenue Guidance, Is The 15% Undervaluation Still There?
Teva Pharmaceutical Industries (NYSE:TEVA) stock is reacting to a mixed update after the company raised its 2026 revenue guidance while reporting a quarterly net loss and new asset impairment charges.
See our latest analysis for Teva Pharmaceutical Industries.
The earnings update and higher 2026 revenue guidance have arrived alongside sharp share price swings, with a 1 day share price return of 9.6% and a 7 day share price return of 15.1%. Over a longer horizon, the 1 year total shareholder return of 106.2% and 3 year total shareholder return above 2.5x suggest that stronger long term momentum has been building over time.
If Teva Pharmaceutical Industries’ latest move has you reassessing opportunities in healthcare, this could be a good moment to see what else is setting up in 41 healthcare AI stocks
After a sharp move and fresh guidance from Teva Pharmaceutical Industries, the question now is whether the recent re rating already reflects the story or if the current price still leaves clear upside on the table.
Most Popular Narrative: 15.1% Undervalued
On the most followed narrative, Teva Pharmaceutical Industries is priced below an implied fair value of $40.90, compared with the last close at $34.71. That gap rests on a detailed view of how the business mix and pipeline could reshape earnings power over time.
Teva's strategic focus and rapid execution on expanding its innovative branded products (AUSTEDO, AJOVY, UZEDY, and upcoming olanzapine LAI), combined with a robust late-stage pipeline targeting large patient populations, are expected to drive higher-margin topline growth and a more profitable product mix, supporting gross margin and net earnings expansion.
Curious what sits behind that higher margin story? The narrative leans on measured revenue growth, rising profitability and a premium earnings multiple. The detailed assumptions might surprise you.
Result: Fair Value of $40.90 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Teva Pharmaceutical Industries still faces pressure from a heavy debt load above US$15b and relies heavily on a small group of branded drugs.
Find out about the key risks to this Teva Pharmaceutical Industries narrative.
Another View On Teva Pharmaceutical Industries Valuation
That 15.1% implied undervaluation contrasts with how Teva Pharmaceutical Industries is priced on earnings. The stock trades on a P/E of 25.8x compared with 18.1x for peers and 15.7x for the broader US Pharmaceuticals industry, while the fair ratio is 28.2x. That premium raises the question of how much good news is already in the price.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With mixed signals around Teva Pharmaceutical Industries, it helps to move quickly, review the facts, and decide where you stand. To weigh both sides of the story, start with the 3 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Teva Pharmaceutical Industries?
If Teva Pharmaceutical Industries has sharpened your focus, do not stop here. Fresh opportunities often appear where fewer people are looking, so consider expanding your options.
- Broaden your watchlist with companies that screen well on value and quality by reviewing the 49 high quality undervalued stocks.
- Strengthen your income approach by checking stocks that pass the 9 dividend fortresses.
- Prioritize resilience by scanning companies highlighted in the 85 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com